Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

J M van Berge Henegouwen, H van der Wijngaart, L J Zeverijn, L R Hoes, M Meertens, A D R Huitema, L A Devriese, M Labots, H M W Verheul, E E Voest, H Gelderblom

Research output: Contribution to journalReview articlepeer-review

11 Downloads (Pure)

Abstract

INTRODUCTION: The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated melanoma. BRAF mutations are also frequently detected driver mutations in other tumor types, including thyroid carcinoma. Since thyroid carcinoma is not a labeled indication for BRAF/MEKi, a cohort for patients with BRAF V600-mutated thyroid carcinoma was opened within the Drug Rediscovery Protocol (DRUP), a national ongoing pan-cancer multi-drug trial, in which patients receive off-label treatment with approved drugs based on their molecular tumor profile.

RESULTS: Here, we present two patients with BRAF-mutated thyroid carcinoma, who were successfully treated with vemurafenib/cobimetinib administered via a feeding tube. Plasma concentrations of vemurafenib and cobimetinib were determined. A partial response was observed in both patients, but they experienced significant toxicity.

CONCLUSION: Our cases show that vemurafenib/cobimetinib treatment is effective in BRAF V600-mutated thyroid carcinoma, also when administered via a feeding tube. Although serious side effects occurred in both patients, we hypothesize that this was not attributable to the administration route. Therefore, administration of vemurafenib/cobimetinib by feeding tube is feasible and effective.

TRIAL REGISTRATION: Clinical trial identification: NCT02925234.

Original languageEnglish
Pages (from-to)97-104
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume90
Issue number1
Early online date22 May 2022
DOIs
Publication statusPublished - Jul 2022

Keywords

  • Case series
  • Cobimetinib
  • Feeding tube
  • Plasma concentrations
  • Thyroid carcinoma
  • Vemurafenib

Fingerprint

Dive into the research topics of 'Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature'. Together they form a unique fingerprint.

Cite this